Host City: China·Shanghai
Date of Event: August 4-5, 2026
Conference scale: 5,000+
Conference format: offline + online live streaming
Organizer: Frost & Sullivan
Scan the QR code to register for the event immediately
The Blue Book is released
"2026 Global AI Medical Industry Development Blue Book" will be released during the Health Technology session of the Life Science New Investment Summit Forum on August 5
In recent years, with the continuous development of new generation information technologies such as Big Data, Cloud Computing, and the Internet of Things, especiallyGenerative Artificial IntelligenceWith breakthroughs in large model technology, Artificial Intelligence (AI) is entering a phase of accelerated application worldwide. The healthcare industry, as a data-intensive and highly specialized field, is becoming an important scenario for deep integration of AI. AI is making continuous technical progress in areas such as medical imaging, diagnostic assistance, disease management, drug research and development, and hospital operations management, driving the upgrade of the healthcare service system toward intelligence and precision.
With multiple drivers including policy support, technological maturity, and capital attention, China’s AI healthcare industry is at a critical stage of transitioning from technical validation to large-scale implementation. Industry chain collaboration continues to deepen, niche markets evolve rapidly, and the competitive landscape becomes increasingly clear. How to seize development opportunities during the restructuring of the industrial structure and the upgrading of technological approaches has become a key issue of concern for industry participants.
Overview of Key Contents of the '2026 Global AI Medical Industry Development Blue Book'
|
Overview of the AI Medical Industry Development Landscape |
Frost & Sullivan defines the technical scope and application boundaries of the global AI healthcare industry, and analyzes its evolution stages and structural characteristics from technology validation to large-scale implementation; it also examines the key drivers (technological breakthroughs, policy support, capital investment, clinical needs, etc.) that promote industry development, as well as the differentiated evolution paths in different regions. |
|
Analysis of Key Application Areas of AI in Healthcare |
The Blue Book will focus on the following core areas, analyzing technology distribution, business models, and market potential within the industrial chain (upstream, midstream, and downstream), including applications in clinical diagnosis (medical imaging AI, pathological diagnostic assistance, gene data analysis, etc.), disease treatment and health management (AI-assisted treatment decisions, personalized therapy, chronic disease management, remote patient monitoring, etc.), hospital operations and management (smart hospitals, process optimization, resource allocation, intelligent electronic medical records, etc.), as well as payment and insurance (innovations in healthcare cost control, claim review, health insurance product design, etc.). |
|
Analysis of Global Market Comparison and Business Model Exploration in AI Healthcare |
Comparative analysis of regulatory environments, technology strategies, commercial progress, and ecosystem differences in major markets such as North America, Europe, China, and the Asia-Pacific region; assessment of the maturity and applicable scenarios of mainstream business models including software subscriptions (SaaS), service-based pricing, and integrated hardware-software solutions; analysis of global capital flows, investment hotspots, corporate competition dynamics, and trends in industry concentration. |
|
Analysis of key challenges and future development trends in the AI healthcare industry. |
Identification and analysis of critical challenges faced by the industry, such as data governance and privacy, algorithm interpretability and fairness, clinical validation standards, liability determination, payment mechanisms, and global regulatory coordination; discussion on governance consensus and development directions including risk classification management, full life cycle governance, and multi-party collaboration worldwide; analysis of future development trends in AI healthcare, including multimodal technology integration, return of practicality and economic value, and building a secure, trustworthy patient-centered ecosystem. |
|
Introduction to AI healthcare companies. |
The Blue Book will include partner companies, presenting their business areas, product portfolios, technical platforms, and differentiated advantages within the AI healthcare industry chain, highlighting the product features and competitive strengths of each partner. |
Highlights from the previous event.
Review of the previous forum:Strengthening foundations, navigating challenges—The 2025 Frost & Sullivan Life Science New Investment Summit successfully concluded!
For more summit information and inquiries
Life Science New Investment Summit
Event consultation | Sponsorship cooperation | Attendance inquiry
📞 Conference consultation hotline:
021-3209-6800 ext. 8672
📧 Conference consultation email:
gil@frostchina.com
